ADCT ADC Therapeutics SA
ADC Therapeutics SA (ADCT) is expected to report earnings on November 12, 2026, before the market open. The consensus earnings estimate is a loss of $0.21 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -5.6% since its last earnings release on August 13, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About ADC Therapeutics SA
ADC Therapeutics is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs).
Sector
Healthcare
Industry
Biotechnology